News

Aripiprazole outperforms paliperidone palmitate in head-to-head trial

Publish date: April 2, 2015

 

AT THE INTERNATIONAL CONGRESS ON SCHIZOPHRENIA RESEARCH

References

This trial was underwritten by Otsuka, makers of Abilify Maintena, and by H. Lundbeck A/S. Dr. Potkin is on the speakers bureau for Otsuka, Forest, and Sunovion, and serves on advisory boards of Alkermes, Forest, Genetech, Lundbeck, Otsuka, Roche, Sunovion, and Takeda.

wmcknight@frontlinemedcom.com

On Twitter @whitneymcknight

Pages

Recommended Reading

Schizophrenia prevention opportunities are emerging
MDedge Psychiatry
Schizophrenia, but not bipolar disorder, linked to social cognition deficits
MDedge Psychiatry
Abnormal calcium level in a psychiatric presentation? Rule out parathyroid disease
MDedge Psychiatry
Oversight of antipsychotic use in Medicaid-insured children varies by state
MDedge Psychiatry
Dimensional aspects of DSM-5 personality disorder criteria discussed
MDedge Psychiatry
Schizophrenia patients twice as likely to be at risk for DVT and PE
MDedge Psychiatry
Impaired self-assessment in schizophrenia: Why patients misjudge their cognition and functioning
MDedge Psychiatry
FDA calls study of unexplained olanzapine deaths ‘inconclusive’
MDedge Psychiatry
Three-month injectable paliperidone palmitate delayed relapse in schizophrenia up to 1 year
MDedge Psychiatry
Benzodiazepine reduction without withdrawal symptoms possible in patients with schizophrenia, bipolar disorder
MDedge Psychiatry